DE60217315D1 - Pharmazeutische zusammensetzungen von rapamycines - Google Patents

Pharmazeutische zusammensetzungen von rapamycines

Info

Publication number
DE60217315D1
DE60217315D1 DE60217315T DE60217315T DE60217315D1 DE 60217315 D1 DE60217315 D1 DE 60217315D1 DE 60217315 T DE60217315 T DE 60217315T DE 60217315 T DE60217315 T DE 60217315T DE 60217315 D1 DE60217315 D1 DE 60217315D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
rapamycines
ascomycin
prevention
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217315T
Other languages
English (en)
Other versions
DE60217315T2 (de
Inventor
Dorothea Ledergerber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60217315D1 publication Critical patent/DE60217315D1/de
Application granted granted Critical
Publication of DE60217315T2 publication Critical patent/DE60217315T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60217315T 2001-04-04 2002-04-03 Pharmazeutische zusammensetzungen von rapamycines Expired - Lifetime DE60217315T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0108498 2001-04-04
GBGB0108498.7A GB0108498D0 (en) 2001-04-04 2001-04-04 Organic Compounds
PCT/EP2002/003694 WO2002080978A2 (en) 2001-04-04 2002-04-03 Pharmaceutical compositions comprising ascomycin

Publications (2)

Publication Number Publication Date
DE60217315D1 true DE60217315D1 (de) 2007-02-15
DE60217315T2 DE60217315T2 (de) 2007-05-31

Family

ID=9912264

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217315T Expired - Lifetime DE60217315T2 (de) 2001-04-04 2002-04-03 Pharmazeutische zusammensetzungen von rapamycines

Country Status (13)

Country Link
US (3) US20040171599A1 (de)
EP (1) EP1377315B1 (de)
JP (1) JP4927310B2 (de)
CN (2) CN100358580C (de)
AT (1) ATE350064T1 (de)
AU (1) AU2002310920A1 (de)
BR (1) BR0208655A (de)
CA (1) CA2443235C (de)
DE (1) DE60217315T2 (de)
GB (1) GB0108498D0 (de)
HK (1) HK1061647A1 (de)
PT (1) PT1377315E (de)
WO (1) WO2002080978A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594484A2 (de) * 2003-02-17 2005-11-16 Cipla Ltd. Pharmazeutisches pflaster
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
DK1734927T3 (da) * 2004-04-08 2012-09-24 Meda Pharma S A R L Pimecrolimusskumsammensætning indeholdende hexylenglycol, eventuelt oleylalkohol, dimethylisosorbid og/eller middelkædede triglycerider
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US9855243B2 (en) 2013-10-30 2018-01-02 Qurient Co., Ltd. Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
KR101462474B1 (ko) * 2013-10-30 2014-11-19 주식회사 큐리언트 질레우톤 크림 제형의 국소용 항염증 약학적 조성물
KR20180002822A (ko) * 2015-05-08 2018-01-08 비버스 인크. 폐 고혈압의 치료 또는 예방을 위한 방법 및 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
IE66485B1 (en) * 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
PT786986E (pt) * 1994-10-26 2002-07-31 Novartis Ag Formulacoes farmaceuticas
ME00189B (me) * 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
RU2203058C2 (ru) * 1998-04-27 2003-04-27 Фудзисава Фармасьютикал Ко., Лтд. Фармацевтическая композиция
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
EP1377315B1 (de) 2007-01-03
CA2443235A1 (en) 2002-10-17
US20110224246A1 (en) 2011-09-15
PT1377315E (pt) 2007-02-28
BR0208655A (pt) 2004-03-02
US20040171599A1 (en) 2004-09-02
EP1377315A2 (de) 2004-01-07
GB0108498D0 (en) 2001-05-23
JP2004525169A (ja) 2004-08-19
WO2002080978A2 (en) 2002-10-17
US20070298058A1 (en) 2007-12-27
CN1501814A (zh) 2004-06-02
CA2443235C (en) 2011-03-15
WO2002080978A3 (en) 2003-10-30
CN1226047C (zh) 2005-11-09
ATE350064T1 (de) 2007-01-15
AU2002310920A1 (en) 2002-10-21
JP4927310B2 (ja) 2012-05-09
CN100358580C (zh) 2008-01-02
CN1679962A (zh) 2005-10-12
DE60217315T2 (de) 2007-05-31
HK1061647A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TR200103493T2 (tr) Metaloproteaz önleyicileri
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
SE0101932D0 (sv) Pharmaceutical combinations
CY1110664T1 (el) Ενδορινικες συνθεσετς
ATE495187T1 (de) Dalda-analoge und ihre verwendung
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
DK1187803T3 (da) Amorfe salpetersyreestere og deres farmaceutiske sammensætninger
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
DE60217315D1 (de) Pharmazeutische zusammensetzungen von rapamycines
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
AU2001252419A1 (en) Thrombin inhibitors
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DK1181300T3 (da) 6-O-carbamatketolidderivater
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
EE200400069A (et) Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN